Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction

Clinical Study Results:
The Phase 2b QUALITY clinical study conducted by Veru Inc. demonstrated that enobosarm, when used in conjunction with Wegovy (semaglutide), significantly reduced the loss of lean mass in older patients with obesity or overweight conditions134.

Efficacy Data:

Patients on enobosarm lost 71% less lean mass compared to those receiving Wegovy alone.
There was a 27% greater loss of fat mass in patients taking enobosarm with Wegovy compared to those on Wegovy alone.
The study showed that enobosarm improved body composition by preserving lean mass while promoting fat loss134.

Clinical Significance:

The preservation of lean mass is crucial in older adults to prevent frailty and functional decline.
GLP-1 receptor agonists like Wegovy can lead to significant muscle loss, which may accelerate frailty and muscle weakness in elderly patients15.

Future Plans:

Veru Inc. plans to meet with the FDA to discuss the design of the Phase 3 clinical program based on the promising results from the Phase 2b QUALITY study1.

Market Potential:

The market for treating sarcopenic obesity is substantial, with a significant portion of the older adult population in the US potentially benefiting from a drug that preserves muscle mass during weight loss1.

Sources:

1. https://www.globenewswire.com/news-release/2025/01/27/3015441/11676/en/Veru-Announces-Positive-Topline-Data-from-Phase-2b-QUALITY-Clinical-Study-Enobosarm-Preserved-Lean-Mass-in-Patients-Receiving-WEGOVY-Semaglutide-for-Weight-Reduction.html

3. https://www.biospace.com/drug-development/verus-drug-spares-lean-mass-in-overweight-obese-adults-on-wegovy

4. https://www.bloomberg.com/news/articles/2025-01-27/us-biotech-says-drug-thwarted-muscle-loss-in-wegovy-patients

5. https://www.medicalnewstoday.com/articles/how-to-preserve-muscle-mass-on-weight-loss-drugs-like-wegovy